

Paris & Toulouse, April 1<sup>st</sup>, 2015

## 2014 Reference Document Available with Annual Financial Report

Genticel (Euronext Paris and Brussels: FR0011790542 - GTCL), a French biotechnology company and leading developer of therapeutic vaccines, announces that its reference document 2014 was registered, on March 31<sup>st</sup>, 2015, under the number R.15-015 by the AMF (*Authorité des marchés financiers*).

The 2014 reference document notably includes:

- 2014 annual financial report;
- the Supervisory Board's Chairman report as stipulated by Article L.225-68 of the French Commercial Code and the corresponding external auditor report;
- the fees for external auditors;
- the company's activities in terms of social, environmental and community impact.

This document \*can be consulted on the Genticel website ([www.genticel.com](http://www.genticel.com), Investors section) and on the AMF website ([www.amf-france.org](http://www.amf-france.org)). Copies of the document are available upon request, free of charge, at the registered office of the Company, 516 Rue Pierre et Marie Curie, Prologue Biotech, 31670 Labège - France.

**Note (\*): Document only available in French at the date of registration**

### About Genticel

*Genticel is a French biopharmaceutical company specialized in the development of therapeutic vaccines aimed at eliminating, at an early stage, the human papillomavirus (HPV) responsible for cervical cancer.*

*Genticel's most advanced candidate therapeutic vaccine, ProCervix, is currently in a Phase 2 clinical trial. ProCervix is designed to induce the elimination of cervical cells infected with HPV 16 and/or HPV 18. The company has also established Vaxiclase, a technology platform ideally adapted for use in early-intervention immunotherapies against multiple infectious or cancerous diseases. This platform is being used to develop a second therapeutic vaccine candidate, now in its preclinical stage, targeting six of the most pertinent HPV strains in terms of global epidemiology.*

*In 2015, Genticel licensed its Vaxiclase technology to Serum Institute of India Ltd. (SII), the largest vaccine producer in the world, for use as a component in acellular multivalent combination vaccines including pertussis antigens.*

*Genticel is based in Paris and Toulouse and was awarded 2014 "Prix Biotech d'Avenir" (Most Promising Biotech) in the SW France category of the Deloitte Technology Fast 50 Benchmark.*

*Since April 4, 2014, Genticel shares have been listed on the regulated Euronext markets in Paris and Brussels.*

*For more information, please visit Genticel's website, [www.genticel.com](http://www.genticel.com)*



**GENTICEL CONTACT**  
Benedikt Timmerman  
Chief Executive Officer  
[investors@genticel.com](mailto:investors@genticel.com)

**USA INVESTOR CONTACT**  
Brian Stollar  
Tel.: +1 (212) 915 2577  
[bstollar@lifesciadvisors.com](mailto:bstollar@lifesciadvisors.com)

**INVESTOR CONTACT**  
Corinne Puissant  
Tel.: +33 (0)1 53 67 36 77  
[cpuissant@actus.fr](mailto:cpuissant@actus.fr)

**PRESS CONTACT**  
Alexandra Prisa  
Tel.: +33 (0)1 53 67 36 90  
[aprisa@actus.fr](mailto:aprisa@actus.fr)